Nexus Pharmaceuticals, Inc.

Belkins
Nexus Pharmaceuticals, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

APHA: TRANSPARENCY, SAFETY AND AVAILABILITY MUST BE CORE PRINCIPLES FOR STRENGTHENING AMERICA'S DRUG SUPPLY CHAIN

APhA | August 11, 2020

news image

The reliability, quality and safety of our nation's drug supply chain are essential to the nation's security and health and well-being of the American public. Therefore, we welcome comprehensive federal efforts to improve the state of our drug supply chain, particularly at a time when our health care system is under extraordinary stress. The President's Executive Order last week, "Ensuring Essential Medicines, Medical Countermeasures and Critical Inputs Are Made in the United St...

Read More

PHARMA TECH

FEDS REBUFF PFIZER'S PLEAS TO SPEED UP SUPPLIES OF COVID-19 VACCINE RAW MATERIALS

Pfizer | December 21, 2020

news image

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in it...

Read More

BIG PHARMA GROUNDS EMPLOYEES: GSK, BRISTOL, ROCHE, SANOFI AND MORE LIMIT TRAVEL DUE TO CORONAVIRUS

FiercePharma | March 06, 2020

news image

Biopharma companies are hunkering down as the COVID-19 epidemic breaks out worldwide. In a FiercePharma survey of biopharma companies late last month, most drugmakers said they were simply limiting travel to hard-hit countries such as China, South Korea and Italy. Now, as more cases pop up across the U.S., Europe and Asia, their tone has shifted. GlaxoSmithKline has “instructed all employees to postpone non-critical international business travel until further notice,” a spokesman sai...

Read More

PHARMACY MARKET

FUSION PHARMACEUTICALS AND TRIUMF ANNOUNCE EXPANDED R&D COLLABORATION FOR ACTINIUM SUPPLY PRODUCTION

Fusion Pharmaceuticals Inc. | August 13, 2021

news image

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator centre, today announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have ...

Read More

APhA | August 11, 2020

news image

APHA: TRANSPARENCY, SAFETY AND AVAILABILITY MUST BE CORE PRINCIPLES FOR STRENGTHENING AMERICA'S DRUG SUPPLY CHAIN

The reliability, quality and safety of our nation's drug supply chain are essential to the nation's security and health and well-being of the American public. Therefore, we welcome comprehensive federal efforts to improve the state of our drug supply chain, particularly at a time when our health care system is under extraordinary stress. The President's Executive Order last week, "Ensuring Essential Medicines, Medical Countermeasures and Critical Inputs Are Made in the United St...

Read More

PHARMA TECH

Pfizer | December 21, 2020

news image

FEDS REBUFF PFIZER'S PLEAS TO SPEED UP SUPPLIES OF COVID-19 VACCINE RAW MATERIALS

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in it...

Read More

FiercePharma | March 06, 2020

news image

BIG PHARMA GROUNDS EMPLOYEES: GSK, BRISTOL, ROCHE, SANOFI AND MORE LIMIT TRAVEL DUE TO CORONAVIRUS

Biopharma companies are hunkering down as the COVID-19 epidemic breaks out worldwide. In a FiercePharma survey of biopharma companies late last month, most drugmakers said they were simply limiting travel to hard-hit countries such as China, South Korea and Italy. Now, as more cases pop up across the U.S., Europe and Asia, their tone has shifted. GlaxoSmithKline has “instructed all employees to postpone non-critical international business travel until further notice,” a spokesman sai...

Read More

PHARMACY MARKET

Fusion Pharmaceuticals Inc. | August 13, 2021

news image

FUSION PHARMACEUTICALS AND TRIUMF ANNOUNCE EXPANDED R&D COLLABORATION FOR ACTINIUM SUPPLY PRODUCTION

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator centre, today announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have ...

Read More